Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to sign a written consent form for the study.
- People who have been diagnosed with melanoma (confirmed through a tissue sample) for which their doctor has recommended a Sentinel Lymph Node Biopsy (a procedure to check nearby lymph nodes for cancer spread).
- People with melanoma that started on the skin or in mucous membranes (such as inside the mouth or nose) are eligible.
- Women who could become pregnant must have a negative pregnancy test (urine or blood) within 7 days before receiving the study drug.
- Women who are considered unable to become pregnant — because they have gone through menopause (no periods for at least 12 months), have had a hysterectomy, removal of both ovaries or fallopian tubes, or have a medical condition that prevents pregnancy — meet this particular requirement.
- Women and men of reproductive age must agree to avoid pregnancy during the study and for a short time afterward (1 week for women, 2 weeks for men), either by not having heterosexual sex or by using an accepted form of contraception.
- People with adequate blood counts: enough white blood cells, platelets, and haemoglobin (confirm specific numbers with trial site).
- People with adequate kidney function, based on a blood test for creatinine (confirm with trial site).
- People with adequate liver function, based on blood tests for certain liver markers (confirm with trial site).
Who may not be able to join:
- People who have a known condition that weakens their immune system long-term, or who take certain medications that suppress the immune system (such as infliximab, mycophenolate, methotrexate, or prednisone at doses above 20 mg daily).
- People who have had a serious blood infection or severe infection in the 4 weeks before entering the study.
- People who have a history of nerve damage (neuropathy) caused by chemotherapy or other non-cancer-related reasons.
- People who are pregnant or breastfeeding.
- People who are in very poor physical condition and are completely unable to care for themselves (based on a standard medical performance scale).
- People who have taken another experimental/investigational drug within 2 weeks — or within 6 half-lives of that drug, whichever timeframe is shorter — before joining the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yana M Najjar, MD, UPMC Hillman Cancer Center
Phone: 4126231191
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Tumor Hypoxia; Progression Free Survival; Sentinel Lymph Node Hypoxia
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.